Pharmaceuticals, Biotechnology and Life Sciences
Bristol Myers Squibb presented results from the Phase 3 CheckMate -9DW trial evaluating the dual immunotherapy combination of Opdivo® (nivolumab) plus Yervoy® (ipilimumab)…
The European Commission (EC) has approved Bristol Myers Squibb’s Opdivo (nivolumab) in combination with Yervoy (ipilimumab) for the first-line treatment of adult patients with unresectable advanced, recurrent or metastatic esophageal squamous cell carcinoma (ESCC) with tumor cell PD-L1 expression ≥ 1%.
The European Medicines Agency (EMA) has validated Bristol Myers Squibb-s type II variation application for Opdivo (nivolumab) in combination with chemotherapy for the neoadjuvant treatment of patients with resectable stage IB to IIIA non-small cell lung cancer (NSCLC), based on results from the CheckMate -816 trial.
UbiVac has announced working with BMS on Phase Ib study to combine UbiVac’s DRibble® Platform Vaccine, DPV-001 with anti-OX40 (BMS-986178) and Opdivo (nivolumab) to test hypothesis that this combination will augment anticancer immunity in advanced triple negative breast cancer.
PRINCETON, N.J.–(BUSINESS WIRE)–$BMY #BMS—Bristol-Myers Squibb Company (NYSE: BMY) today announced that the European Commission (EC) has approved Opdivo (nivolumab) flat…
Bristol-Myers Squibb study evaluated Opdivo plus low-dose Yervoy given concomitantly with two cycles of chemotherapy vs. chemotherapy alone for the…
Opdivo demonstrated a 23% reduction in the risk of death and 2.5-month improvement in median overall survival compared to chemotherapy, according to results from Phase 3 ATTRACTION-3 trial to be featured in a Presidential Symposium during the European Society for Medical Oncology 2019 Annual Congress.
Bristol-Myers squib’s Opdivo combined with Yervoy resulted in 52% of patients with being alive at five years, while 74% of patients treated with Opdivo plus Yervoy who were alive at five years remained treatment-free, the longest follow-up to date results for dual Immuno-Oncology (I-O) therapy in a Phase 3, randomized, controlled trial showed.
Bristol Myers Squib’s adjuvant treatment with Opdivo (nivolumab) further showed extended recurrence-free survival at three years in resected high-risk melanoma patients, being the longest follow-up of any PD-1 inhibitor in the adjuvant melanoma setting.
Overall survival data from CheckMate -227 Part 1 evaluating Opdivo (nivolumab) plus low-dose Yervoy (ipilimumab) in advanced non-small cell lung cancer featured in ESMO Presidential Symposium